Clinical study of YS110

Phase 1 clinical study in France (sponsored by Y’sAC) was completed in 2015 and published in British Journal of Cancer on March 14, 2017 with the conclusions as shown:

1) Safety : The safety of YS110 was confirmed in the dose escalation study of YS110 as 0.1, 0.4,1.0,2.0,4.0, and 6.0mg/kg with an administration frequency of once by 2 weeks or once a week.

2) Efficacy: Suggestive clinical efficacy was observed in RECIST evaluation as 13 SD and 13 PD in total 26 evaluable cases consisting of 19, 6, and one cases of malignant mesothelioma, renal cell carcinoma, and urothelial carcinoma, respectively.Disease controlled status was observed in 7 cases with progression free survival period of longer than 180 days ( longest duration of 399 days on a patient with malignant mesothelioma).

3) Biomarkers: the serum soluble CD26/DPP4 titers were decreased in correlation with YS110 administration. The phenomenon shall give the opportunity to be a biomarker for the cancer therapy. 4) Combination therapy with YS110 was warranted for Phase 2 clinical study based on the results of the Phase1 study and preclnical study.

Substance under development stage in clinical study----continued

YS110 Phase1/2 clinical study in Japan is on going on patients with malignant mesothelioma sponsored by Kissei pharmaceutical Co., Ltd. in Japan, under licensed by Y’sAC on exclusive right of development, selling, and production of YS110 for the treatment of patients with malignant mesothelioma in the territory of Japan.